Cannabis–based products
Guidance to clinicians
Following the Government’s announcement to reschedule certain cannabis-based products for medicinal use from 1 November 2018, NHS England has provided guidance to clinicians following the re-scheduling which sets out our expectations of what this regulatory change will mean in practice for clinicians working in the NHS and in private practice in England.
Under the proposed new regime, all cannabis-based products for medicinal use apart from Sativex® (which has a market authorisation) would be unlicensed medicines.
Information for patients
Information for patients and the public explaining what the changes mean is available on the NHS website here: https://www.nhs.uk/conditions/medical-cannabis/
MHRA guidance
Supply unlicensed medicinal products (specials)
Guidance on manufacturing, importing, distributing and supplying specially manufactured or ordered products, including cannabis-based products for medicinal use in humans (CBPMs), known as 'specials'
This drug can be found on the following pages:
-
BNF
-
NICE
-
Summary of product characteristics
